Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report

Canine cutaneous epitheliotropic T-cell lymphoma (CETL) is associated with a poor prognosis and without consistently beneficial treatment options. This case report describes a 9-year-old Staffordshire bull terrier with CETL treated with oclacitinib (0.7 mg/kg twice daily), resulting in partial remission that was maintained for three months. Further studies are warranted.

Authors: J. Aslan, M. A. Shipstone and L. M. Sullivan Title: Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report Full source: Vet Dermatol, 2021,Vol 32, Iss 4, pp 398-e113
Résumé, analyse et commentaires
Aucun.
Photo
Aucune.
Analysis
None.
Abstract	Source
Canine cutaneous epitheliotropic T-cell lymphoma (CETL) is associated with a poor prognosis and without consistently beneficial treatment options. This case report describes a 9-year-old Staffordshire bull terrier with CETL treated with oclacitinib (0.7 mg/kg twice daily), resulting in partial remission that was maintained for three months. Further studies are warranted.